MetLife Inc.
Index to Business Page Business Overview & Strategy 5 Segments and Corporate & Other 6 Policyholder Liabilities 10 Underwriting and Pricing 11 Reinsurance Activity 12 Regulation 12 Competition 23 Human Capital Resources 24 Information About Our Executive Officers 25 Trademarks 26 Available Information 26 4 Table of Contents Business Overview & Strategy As used in this Form 10-K, MetLife, the Co…
$102.18
+$1.00 (+0.99%)
Price from 2 days ago
Net margin is thin at 4.38%. This may reflect rising credit costs, rate compression, or operational inefficiency.
Revenue grew 8.6% YoY. However, net income declined 24%, rising credit provisions or expenses may be eating into the top line.
At 20x earnings, the multiple is above the banking sector average. Financials rarely sustain elevated multiples through credit cycles. Net income declined 24% YoY, profitability momentum has weakened.
19.5x earnings. Above the financial-sector median (~13x). The market is pricing in above-average returns or growth, any credit deterioration would compress the multiple quickly.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$79.40B
▲ +8.6% YoY
Net Income (TTM)
$3.62B
▼ -23.7% YoY
Net Margin
4.55%
P/E
19.5x
Balance Sheet
Total Assets
$759.37B
Equity
$27.44B
Total Debt
$746M
Cash & Equiv.
$27.32B
5Y CAGR: +2.6%
Continue Research
SourceComputed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 2 Oct 2026. How this is calculated.
Price from market data, last close as of 21 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is MetLife (MET) overvalued?
At a P/E of 19.5, MetLife (MET)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, MetLife scores 65/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 2.3%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is MetLife a high-quality business?+
MetLife scores 65 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 8.3% operating margin and a 18.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Does MetLife (MET) pay a dividend, and how much?+
Yes, MetLife pays a regular dividend of about $2.33 per share per year (typically in quarterly installments), a yield of roughly 2.3% at the current price. That is a payout ratio of about 41.7% of earnings, so the dividend is well covered. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For MET's full payout history, growth streak and dividend-safety score, see the dividends tab.
Is MetLife a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh MET's valuation and scores 65/100 on quality (solid). It also yields about 2.3%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Life Insurance
Spot a number that looks wrong? Check it in MET's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing MET
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.